Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Compugen doses first patient in Phase l trial of COM701

Histopathologic representation of endometrioid adenocarcinoma demonstrated in endometrial biopsy. Credit: KGH.



Go Top